The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed
Kathryn Drysdale12, Yevedzo Ntuli13, Jonathan Bestwick4, William Gelson5, Kosh Agarwal3, Daniel Forton6, David Mutimer7, Ahmed M Elsharkawy7, Ceri Townley8, Faizel Mahomed9, Graham R Foster12
1Barts Liver Centre, Blizard Institute, Queen Mary University of London, London, UK.
2Barts Health NHS Trust, London, UK.
3Institute of Liver Studies, King's College Hospital, London, UK.
4Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK.
5Cambridge Liver Unit, Cambridge, UK.
6St George's University NHS Trust, London, UK.
7NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK.
8Specialised Services National Support team, NHS England, Southampton, UK.
9NHS Arden and Greater East Midlands Commissioning Support Unit, Leicester, UK.
Abstract
Background: In England, choice of hepatitis C therapy is determined by national contracts that change with time, facilitating comparisons between different regimens. England has a diverse population with hepatitis C including large proportions of uncommon viral genotypes.
Aim: To evaluate efficacy of directly acting anti-viral treatments for hepatitis C in England using real-world data from the national treatment registry.
Methods: Sustained virological response (SVR) rates 12 weeks after treatment completion for patients treated between 2014 and August 2018 who attended for SVR tests were analysed in univariate subgroups using Chi-squared tests. Multivariate models were constructed with clinically relevant variables to determine predictors of SVR and evaluate the impact of treatment regimens.
Results: SVR data were available on 14,603 treated patients. The overall SVR rate was 95.59% [95% CI 95.25%-95.91%]. Multivariable regression modelling in patients with genotype 1 infection showed that the odds of SVR with elbasvir/grazoprevir were higher than for those treated with sofosbuvir/ledipasvir (OR 1.891, 95% CI 1.072-3.336, P = 0.028). For genotype 3, we found no significant difference between any of the treatment regimens.
Patients who completed at least one third of the planned treatment duration achieved SVR rates in excess of 80%.
Conclusions: All of the currently licensed hepatitis C direct-acting anti-viral regimens had similar efficacy (>95%) in an unselected population. Noncompletion of planned treatment duration still resulted in over 80% SVR rates provided that more than one third of treatment was completed.